Use of Leukotriene Receptor Antagonists Are Associated with a Similar Risk of Asthma Exacerbations as Inhaled Corticosteroids

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 5, 2014, Pages 607-613

  Wu, Ann Chen ^a,b   Li, Lingling ^a   Fung, Vicki ^c   Kharbanda, Elyse O ^d   Larkin, Emma K ^e   Vollmer, William M ^f   Butler, Melissa G ^g   Miroshnik, Irina ^a   Rusinak, Donna ^a   Davis, Robert L ^g   Hartert, Tina ^e   Weiss, Scott T ^h,i   Lieu, Tracy A ^a,b,j  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d HEALTHPARTNERS INSTITUTE   (United States)

^e VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f CENTER FOR HEALTH RESEARCH   (United States)

^g KAISER PERMANENTE   (United States)

^h BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁱ LABORATORY FOR MOLECULAR MEDICINE   (United States)

^j DIVISION OF RESEARCH   (United States)

more..

Author keywords

Asthma; Controller medications; ED; Effectiveness; HdPS; HPHC; HR; ICS; Inhaled corticosteroids; KPGA; KPNC; KPNW; LABA; Leukotriene antagonist; Long acting agonist; LTRA; PDC; PEAL; TennCare

Indexed keywords

ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DRUG THERAPY; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG;

ADOLESCENT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; CHARLSON COMORBIDITY INDEX; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG THERAPY; ELECTRONIC MEDICAL RECORD; EMERGENCY HEALTH SERVICE; EPIDEMIOLOGY; ETHNICITY; FEMALE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICATION COMPLIANCE; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PROPENSITY SCORE; RACE DIFFERENCE; RETROSPECTIVE STUDY; RHINITIS, ALLERGIC; RISK; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, INHALATION; ADOLESCENT; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; DRUG THERAPY; EMERGENCY SERVICE, HOSPITAL; EPIDEMIOLOGY; FEMALE; HOSPITALIZATION; HUMANS; LEUKOTRIENE ANTAGONISTS; MALE; RETROSPECTIVE STUDIES; RHINITIS, ALLERGIC; RISK; STATISTICS AND NUMERICAL DATA; THERAPEUTIC USE; TREATMENT OUTCOME; UNITED STATES;

EID: 84964311365     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.05.009     Document Type: Article

References (41)

1. Szefler S.J., Baker J.W., Uryniak T., Goldman M., Silkoff P.E. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. JAllergy Clin Immunol 2007, 120:1043-1050.
2. Sorkness C.A., Lemanske R.F., Mauger D.T., Boehmer S.J., Chinchilli V.M., Martinez F.D., et al. Long-term comparison of 3 controller regimens for mild-moderate persistent childhood asthma: the Pediatric Asthma Controller Trial. JAllergy Clin Immunol 2007, 119:64-72.
3. Garcia-Garcia M.L., Wahn U., Gilles L., Swern A., Tozzi C.A., Polos P. Montelukast, compared with fluticasone, for control of asthma among 6- to 14-year-old patients with mild asthma: the MOSAIC study. Pediatrics 2005, 116:360-369.
4. Chauhan B.F., Ducharme F.M. Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 2012, (5):CD002314.
5. National Asthma Education and Prevention Program. Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma Update on Selected Topics: 2002. JAllergy Clin Immunol 2002, 110:S141-219.
6. Ducharme F.M., Ni Chroinin M., Greenstone I., Lasserson T.J. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 2010, (5). CD005535.
7. Covar R.A., Szefler S.J., Zeiger R.S., Sorkness C.A., Moss M., Mauger D.T., et al. Factors associated with asthma exacerbations during a long-term clinical trial of controller medications in children. JAllergy Clin Immunol 2008, 122:741-747.e4.
8. O'Byrne P.M., Pedersen S., Busse W.W., Tan W.C., Chen Y.Z., Ohlsson S.V., et al. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 2006, 129:1478-1485.
9. Price D., Hillyer E.V., van der Molen T. Efficacy versus effectiveness trials: informing guidelines for asthma management. Curr Opin Allergy Clin Immunol 2013, 13:50-57.
10. Shepherd J., Rogers G., Anderson R., Main C., Thompson-Coon J., Hartwell D., et al. Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over. Health Technol Assess 2008, 12. iii-iv, 1-360.
11. Colice G.L., Yu A.P., Ivanova J.I., Hsieh M., Birnbaum H.G., Lage M.J., et al. Costs and resource use of mild persistent asthma patients initiated on controller therapy. JAsthma 2008, 45:293-299.
12. Scarfone R.J., Zorc J.J., Capraro G.A. Patient self-management of acute asthma: adherence to national guidelines a decade later. Pediatrics 2001, 108:1332-1338.
13. Ostrom N.K., Decotiis B.A., Lincourt W.R., Edwards L.D., Hanson K.M., Carranza Rosenzweig J.R., et al. Comparative efficacy and safety of low-dose fluticasone propionate and montelukast in children with persistent asthma. JPediatr 2005, 147:213-220.
14. Stempel D.A., Kruzikas D.T., Manjunath R. Comparative efficacy and cost of asthma care in children with asthma treated with fluticasone propionate and montelukast. JPediatr 2007, 150:162-167.
15. Wu A.C., Smith L., Bokhour B., Hohman K.H., Lieu T.A. Racial/ethnic variation in parent perceptions of asthma. Ambul Pediatr 2008, 8:89-97.
16. Kelly H.W., Sternberg A.L., Lescher R., Fuhlbrigge A.L., Williams P., Zeiger R.S., et al. Effect of inhaled glucocorticoids in childhood on adult height. NEngl J Med 2012, 367:904-912.
17. Sherman J., Patel P., Hutson A., Chesrown S., Hendeles L. Adherence to oral montelukast and inhaled fluticasone in children with persistent asthma. Pharmacotherapy 2001, 21:1464-1467.
18. Schneeweiss S., Seeger J.D., Maclure M., Wang P.S., Avorn J., Glynn R.J. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. Am J Epidemiol 2001, 154:854-864.
19. Charlson M., Szatrowski T.P., Peterson J., Gold J. Validation of a combined comorbidity index. JClin Epidemiol 1994, 47:1245-1251.
20. Peterson A.M., Nau D.P., Cramer J.A., Benner J., Gwadry-Sridhar F., Nichol M. Achecklist for medication compliance and persistence studies using retrospective databases. Value Health 2007, 10:3-12.
21. Williams L.K., Peterson E.L., Wells K., Ahmedani B.K., Kumar R., Burchard E.G., et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. JAllergy Clin Immunol 2011, 128:1185-1191.e2.
22. Schneeweiss S., Rassen J.A., Glynn R.J., Avorn J., Mogun H., Brookhart M.A. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009, 20:512-522.
23. Rassen J.A., Glynn R.J., Brookhart M.A., Schneeweiss S. Covariate selection in high-dimensional propensity score analyses of treatment effects in small samples. Am J Epidemiol 2011, 173:1404-1413.
24. Toh S., Garcia Rodriguez L.A., Hernan M.A. Confounding adjustment via a semi-automated high-dimensional propensity score algorithm: an application to electronic medical records. Pharmacoepidemiol Drug Saf 2011, 20:849-857.
25. Diamant Z., Mantzouranis E., Bjermer L. Montelukast in the treatment of asthma and beyond. Expert Rev Clin Immunol 2009, 5:639-658.
26. Yawn B.P. Importance of allergic rhinitis management in achieving asthma control: ARIA update. Expert Rev Respir Med 2008, 2:713-719.
27. Szefler S.J., Phillips B.R., Martinez F.D., Chinchilli V.M., Lemanske R.F., Strunk R.C., et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. JAllergy Clin Immunol 2005, 115:233-242.
28. Zeiger R.S., Szefler S.J., Phillips B.R., Schatz M., Martinez F.D., Chinchilli V.M., et al. Response profiles to fluticasone and montelukast in mild-to-moderate persistent childhood asthma. JAllergy Clin Immunol 2006, 117:45-52.
29. Zeiger R.S., Bird S.R., Kaplan M.S., Schatz M., Pearlman D.S., Orav E.J., et al. Short-term and long-term asthma control in patients with mild persistent asthma receiving montelukast or fluticasone: a randomized controlled trial. Am J Med 2005, 118:649-657.
30. Rand C., Bilderback A., Schiller K., Edelman J.M., Hustad C.M., Zeiger R.S. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. JAllergy Clin Immunol 2007, 119:916-923.
31. Price D.B., Hernandez D., Magyar P., Fiterman J., Beeh K.M., James I.G., et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax 2003, 58:211-216.
32. Ducharme F.M., Noya F.J., Allen-Ramey F.C., Maiese E.M., Gingras J., Blais L. Clinical effectiveness of inhaled corticosteroids versus montelukast in children with asthma: prescription patterns and patient adherence as key factors. Curr Med Res Opin 2012, 28:111-119.
33. Bukstein D.A., Luskin A.T., Bernstein A. "Real-world" effectiveness of daily controller medicine in children with mild persistent asthma. Ann Allergy Asthma Immunol 2003, 90:543-549.
34. Jones C., Santanello N.C., Boccuzzi S.J., Wogen J., Strub P., Nelsen L.M. Adherence to prescribed treatment for asthma: evidence from pharmacy benefits data. JAsthma 2003, 40:93-101.
35. Allen-Ramey F.C., Markson L.E., Riedel A.A., Sajjan S., Weiss K.B. Patterns of asthma-related health care resource use in children treated with montelukast or fluticasone. Curr Med Res Opin 2006, 22:1453-1461.
36. Williams B., Noonan G., Reiss T.F., Knorr B., Guerra J., White R., et al. Long-term asthma control with oral montelukast and inhaled beclomethasone for adults and children 6 years and older. Clin Exp Allergy 2001, 31:845-854.
37. Maspero J.F., Duenas-Meza E., Volovitz B., Pinacho Daza C., Kosa L., Vrijens F., et al. Oral montelukast versus inhaled beclomethasone in 6- to 11-year-old children with asthma: results of an open-label extension study evaluating long-term safety, satisfaction, and adherence with therapy. Curr Med Res Opin 2001, 17:96-104.
38. Allen-Ramey F.C., Duong P.T., Riedel A.A., Markson L.E., Weiss K.B. Observational study of the effects of using montelukast vs fluticasone in patients matched at baseline. Ann Allergy Asthma Immunol 2004, 93:373-380.
39. Sawicki G.S., Smith L., Bokhour B., Gay C., Hohman K.H., Galbraith A.A., et al. Periodic use of inhaled steroids in children with mild persistent asthma: what are pediatricians recommending?. Clin Pediatr (Phila) 2008, 47:446-451.
40. Valovirta E., Boza M.L., Robertson C.F., Verbruggen N., Smugar S.S., Nelsen L.M., et al. Intermittent or daily montelukast versus placebo for episodic asthma in children. Ann Allergy Asthma Immunol 2011, 106:518-526.
41. Robertson C.F., Price D., Henry R., Mellis C., Glasgow N., Fitzgerald D., et al. Short-course montelukast for intermittent asthma in children: a randomized controlled trial. Am J Respir Crit Care Med 2007, 175:323-329.